Hikma Pharmaceuticals to acquire Custopharm

Sep 27, 2021

Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent consideration payable upon the achievement of certain commercial milestones.

Print Page Mail Article